{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:13:05Z","timestamp":1767989585820,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.cmi.2022.02.041","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:41:08Z","timestamp":1646998868000},"page":"1151.e9-1151.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial"],"prefix":"10.1016","volume":"28","author":[{"given":"Mar\u00eda","family":"Trujillo-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Mu\u00f1oz-Muela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Serna-Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusnelkis","family":"Milan\u00e9s-Guisado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Praena-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel","family":"\u00c1lvarez-R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Herrera-Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Romero-Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.02.041_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy","volume":"339","author":"Havlir","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.041_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hiv.12348","article-title":"Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials","volume":"17","author":"Arribas","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2022.02.041_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203452","article-title":"No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients","volume":"13","author":"Gutierrez-Valencia","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.02.041_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148924","article-title":"Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens","volume":"11","author":"L\u00f3pez-Cort\u00e9s","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.02.041_bib5","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.041_bib6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.041_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.041_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2022.02.041_bib9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States","volume":"62","author":"Girouard","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.041_bib10","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/QAD.0000000000000807","article-title":"Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients","volume":"29","author":"Duffau","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2022.02.041_bib11","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2022.02.041_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12879-018-3198-2","article-title":"Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015","volume":"18","author":"Quiros-Roldan","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.041_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12916-018-1046-2","article-title":"Switching to dual\/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study","volume":"16","author":"Mussini","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2022.02.041_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2014.08.011","article-title":"Maintenance of virologic efficacy and decrease in levels of \u03b22-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy","volume":"111","author":"Romero-S\u00e1nchez","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2022.02.041_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/jac\/dkaa058","article-title":"Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir\/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study","volume":"75","author":"Lombardi","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.02.041_bib16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/jac\/dky125","article-title":"Systemic inflammation markers after simplification to atazanavir\/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy","volume":"73","author":"Belmonti","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.02.041_bib17","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir\u2013rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2022.02.041_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0956462419834129","article-title":"CD4\/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment","volume":"30","author":"Monsalvo","year":"2019","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2022.02.041_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12716","article-title":"Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch?","volume":"20","author":"Moreno","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2022.02.041_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171155","article-title":"Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification","volume":"12","author":"Lima","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.02.041_bib21","series-title":"Post hoc power: tables and commentary","author":"Lenth","year":"2007"},{"key":"10.1016\/j.cmi.2022.02.041_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-015-0022-1","article-title":"The rise of multiple imputation: a review of the reporting and implementation of the method in medical research data collection, quality, and reporting","volume":"15","author":"Hayati Rezvan","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2022.02.041_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/QAI.0000000000000966","article-title":"NRTI sparing therapy in virologically controlled HIV-1 infected subjects","volume":"72","author":"Maggiolo","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2022.02.041_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/hiv.12749","article-title":"Switching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot study","volume":"20","author":"Vallejo","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2022.02.041_bib25","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkx068","article-title":"Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir\/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial","volume":"72","author":"Lombardi","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22001185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22001185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:31:09Z","timestamp":1761118269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22001185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1198743X22001185"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.02.041","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.02.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}